SME Times is powered by   
Search News
Just in:   • No permanent friends or enemies; only permanent interests: Defence Minister Singh amid Prez Trump's tariff threats  • Atmanirbharta in defence a 'condition for survival and progress': Rajnath Singh  • Govt to improve India's economic indicators by integrating ocean ecosystem accounts  • Indian stock markets dip 2.2 pc amid tariff concerns; Q1 GDP growth to provide buffer  • India, Japan join hands in push for critical minerals 
Last updated: 26 Nov, 2024  

Healthcare.9.Thmb.jpg India’s healthcare sector grew strongly in Q2 FY25, revenue up by 17.6pc

healthcare
   Top Stories
» No permanent friends or enemies; only permanent interests: Defence Minister Singh amid Prez Trump's tariff threats
» Atmanirbharta in defence a 'condition for survival and progress': Rajnath Singh
» Indian stock markets dip 2.2 pc amid tariff concerns; Q1 GDP growth to provide buffer
» Trump’s ‘dead economy’ jibe falls flat as India’s GDP growth surges to 7.8 pc
» India unleashes bold reforms to mitigate impact of global uncertainties, tariffs: FinMin
Staff Reporter | 26 Nov, 2024

The Healthcare sector in India grew strongly in Q2 of FY25, with revenue increasing by 17.6 per cent year on year (YoY), according to a report.

The report by Axis Securities showed that the healthcare sector also grew strongly by 10.4 per cent in quarter on quarter (QoQ).

Hospital occupancy rates, which rose by 340 basis points (bps) YoY and 470 bps QoQ were a key driver behind the growth.

Further, insurance payers contributed 33 per cent of total revenues in the hospital segment -- marking a 23 per cent YoY and 12 per cent QoQ growth.

However, the insurance penetration continues to remain low, the report said. It also offers room for expansion as awareness and purchasing power increase.

The report noted that cancer and cardiac care continue to drive double-digit growth. This, in addition to rising occupancy rates and Average Revenue Per Occupied Bed (ARPOB), is expected to sustain future growth in the healthcare sector, it added.

The report also recorded strong growth in the Indian pharma sector in Q2 FY25.

Major pharmaceutical companies in India reported a 10 per cent YoY growth in Q2 of FY25. This has been driven by impressive performance in North America and the domestic market.

The Indian Pharmaceutical Market (IPM) grew by 8 per cent YoY, with chronic therapies seeing a 9 per cent increase. However, acute therapies experienced a modest 4 per cent growth due to a weaker season.

The report highlighted that the pharmaceutical sector under coverage recorded a 10.2 per cent YoY and 1.7 per cent QoQ growth, led by a 10.8 per cent YoY increase in North America and a 9.8 per cent YoY rise in the Indian business.

The outlook for the pharmaceutical sector remains positive over the next three years, with a promising pipeline in biosimilars, GLP-1 (glucagon-like peptide-1), and peptides, all of which are important in treating diabetes and other conditions.

Companies with a significant share of chronic therapy portfolios continue to outperform the broader market.

 
Print the Page
Add to Favorite
 
Share this on :
 

Please comment on this story:
 
Subject :
Message:
(Maximum 1500 characters)  Characters left 1500
Your name:
 

 
  Customs Exchange Rates
Currency Import Export
US Dollar
₹84.00
₹82.25
UK Pound
₹104.65
₹108.10
Euro
₹92.50
₹89.35
Japanese Yen ₹56.10 ₹54.40
As on 25 Jul, 2025
  Daily Poll
Who do you think will benefit more from the India - UK FTA in the long run?
 Indian businesses & consumers.
 UK businesses & consumers.
 Both will gain equally.
 The impact will be negligible for both.
  Commented Stories
 
 
About Us  |   Advertise with Us  
  Useful Links  |   Terms and Conditions  |   Disclaimer  |   Contact Us  
Follow Us : Facebook Twitter